The efficacy of swicthing from sulfonyl urea to the combination therapy with mitiglinide and voglibose on diurnal variation on glycemic control and endothelial function in patients with type 2 diabetes

The efficacy of swicthing from sulfonyl urea to the combination therapy with mitiglinide and voglibose on diurnal variation on glycemic control and endothelial function in patients with type 2 diabetes - The effect of combination therapy with mitiglinide and voglibose on endothelial function in patients with type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015638

Enrollment

Registered

2014-11-12

Start date

2014-11-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

The combination theraphy with 30 mg of mitiglinide and 0.6 mg of voglibose

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetic patients treated with low dose of sulfonyl urea Glimepiride/Glibenclamide/Gliclazide equal to or lower than 1 mg/1.25 mg/20 mg per day HbA1c; 6.5 - 7.5%

Exclusion criteria

Exclusion criteria: Patients treated with alphaGIs or glinides or insulin. Patients with infection, malignancy, severe liver, renal dysfuction. Pregnant patients. Patients who are unable to be responsible for informed concent due to dementia or impaired consciousness. Patients with past history of intestinal obstruction. Patients who has stared a new regimen of treatment for diabetes within 3 month prior to the registration of this study.

Design outcomes

Primary

Measure	Time frame
The change in FMD, measured by B-mode ultrasound, after 12 weeks	—

Secondary

Measure	Time frame
The change in diurnal glycemic control assessed by continuous glucose monitoring after 12 weeks The change in HbA1c after 12 weeks	—

Countries

Japan

Contacts

Public ContactRyotaro Bouchi

Tokyo Medical and Dental University Departmet of Molecular Endocrinology and Metabolism

bouchi.mem@tmd.ac.jp03-5803-5216

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026